Costs of R&D
Contribute to improve and update this page!
We particularly welcome suggestions on additional data sources
KEI has put together an overview of different estimates of drug development costs. Those estimates have been published by academics, organisations and institutes. KEI compared their diverse calculations.
The Portfolio-To-Impact (P2I) Model allows users to model scenarios and estimate the costs of developing health technologies for neglected diseases. The Supplementary Files contain data on average R&D costs per phase by technology type, length of phase, and probability of success; data on the current neglected disease product pipeline is also included.